TrialThe Journal of allergy and clinical immunology2008

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Miguel L Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.